A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients With Lower Risk Myelodysplastic Syndrome (MDS) With Low Red Blood Cell (RBC) Transfusion Burden (LTB)
Latest Information Update: 15 May 2025
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms MATTERHORN
- Sponsors FibroGen
Most Recent Events
- 12 May 2025 According to a FibroGen media release, company filed Type-C meeting request with FDA for roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) and expect feedback on potential path forward in 3Q 2025
- 01 Sep 2024 Results published in the American Journal of Hematology
- 04 Feb 2024 This trial has been discontinued in Italy.